US Government As Represented by the Secretary of the Army

Virginia Tech Intellectual Properties, Inc.

Nammalwar Sriranganathan

Gerhardt G Schurig

Stephen M Boyle

Richard Lloyd Warren

Luther E Lindler

David Hoover

Mikeljon Nikolich

Ted L Hadfield

Aloka B Bandara

John R McOulston

A recombinant, attenuated strain oforwith a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to thespecies is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.

Development of a live, attenuated, recombinant vaccine for Brucellosis

Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of Brucella which results in attenuation of the strain while retaining the desired immunogenicity to initiate a protective immunogenic response. Other strains with varying levels of attenuation are described.

Live vaccine against Brucellosis

Growing community of inventors

Blacksburg, VA, United States of America

Nammalwar Sriranganathan